LC
ADPT icon

Lindbrook Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Lindbrook Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.5K Buy
1,416
+20
+1% +$154 ﹤0.01% 1631
2024
Q4 		$8.37K Hold
1,396
– – ﹤0.01% 1744
2024
Q3 		$7.15K Hold
1,396
– – ﹤0.01% 1842
2024
Q2 		$5.05K Buy
1,396
+634
+83% +$2.01K ﹤0.01% 1986
2024
Q1 		$2.45K Buy
762
+229
+43% +$886 ﹤0.01% 2169
2023
Q4 		$2.61K Buy
533
+435
+444% +$1.99K ﹤0.01% 2172
2023
Q3 		$534 Buy
98
+19
+24% +$126 ﹤0.01% 2521
2023
Q2 		$530 Sell
79
-458
-85% -$3.4K ﹤0.01% 2496
2023
Q1 		$4.74K Sell
537
-75
-12% -$661 ﹤0.01% 1870
2022
Q4 		$4.68K Buy
612
+528
+629% +$4.11K ﹤0.01% 1864
2022
Q3 		$1K Hold
84
– – ﹤0.01% 2210
2022
Q2 		$1K Buy
+84
New +$739 ﹤0.01% 2126

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's ADPT Position: Q1 2025 in Review

Lindbrook Capital increased its Adaptive Biotechnologies (ADPT) stake by 1.4% in Q1 2025, buying an estimated $154 and bringing the position to 1,416 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

Lindbrook Capital first reported a position in ADPT in Q2 2022 and has held it in 12 quarters since. 225 funds tracked by Wall St. Rank hold ADPT as of Q1 2025.

  • Lindbrook Capital held 1,416 shares of Adaptive Biotechnologies worth $10.5K as of Q1 2025.
  • Lindbrook Capital bought 20 Adaptive Biotechnologies shares in Q1 2025, an estimated $154.
  • Adaptive Biotechnologies made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1631 holding.
  • Lindbrook Capital first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 12 quarters since.
  • 225 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.